Obesity is an epidemic in the America. Four in 10 U.S. adults fit the medical definition of having obesity, which puts them at risk for serious health problems, including diabetes, heart disease ...

Sep. 23, 2024 — With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might ... A Simple Blood Test Warns ...

England's obesity crisis is laid bare today in sobering interactive graphics that reveal the age group most likely to face ...

Dual-action obesity drug rewires brain circuits for appetite Because metabolic diseases are characterized by inflammation in the hypothalamus 5, Beddows and colleagues investigated whether ...

Obesity is high and holding steady in the U.S. About 4 in 10 Americans have obesity overall and about 1 in 10 have severe obesity Obesity is high and holding steady in the U.S., but the proportion ...

The CDC defines obesity as having a body mass index (BMI) of at least 30, and a shocking 20% of Americans meet that criteria, with the Midwest and the South reporting the highest levels of weight.

She is co-writing a book about nutrition and health. “Obesity is a disease,” Oprah Winfrey declared after disclosing her weight loss with an Ozempic-like drug. “It’s a brain disease,” a ...

Should kids do the same? Now a trial has produced some of the first data on anti-obesity drugs in even younger children: those aged 6–11 years. The study 3 reports that children who were treated ...

To address soaring rates of childhood obesity, the American Academy of Pediatrics last year endorsed tactics it once considered risky. “Watchful waiting” had been standard practice ...

BioAge's lead drug, azelaprag, is being developed to treat obesity, in combination with GLP-1 agonists such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy. Affiliates of existing investor ...

The trend comes as anti-obesity drug developers have attracted Wall Street interest and secured the support of several venture capital heavyweights. Some analysts estimate that the market for ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a ...